Continuous stress disrupts immunostimulatory effects of IL-12

Brain, Behavior, and Immunity

Volumn 25, Issue 4, 2011, Pages 727-735

  Levi, Ben ^a   Benish, Marganit ^a   Goldfarb, Yael ^a   Sorski, Liat ^a   Melamed, Rivka ^a   Rosenne, Ella ^a   Ben Eliyahu, Shamgar ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

IL 12; MADB106; Metastases; NK activity; Stress

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; INTERLEUKIN 12;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIORAL STRESS; CELL COUNT; CONTROLLED STUDY; DRUG EFFECT; FEMALE; IMMUNOSTIMULATION; IN VIVO STUDY; LUNG ALVEOLUS CELL; LUNG CLEARANCE; LUNG TUMOR; MALE; NATURAL KILLER CELL; NONHUMAN; PHARMACOLOGIC STRESS TESTING; PHYSIOLOGICAL STRESS; PRIORITY JOURNAL; RAT;

ADENOCARCINOMA; ADJUVANTS, IMMUNOLOGIC; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ANALYSIS OF VARIANCE; ANIMALS; CHRONIC DISEASE; CORTICOSTERONE; EPINEPHRINE; FEMALE; INTERLEUKIN-12; KILLER CELLS, NATURAL; LUNG NEOPLASMS; MALE; METAPROTERENOL; NEOPLASMS, EXPERIMENTAL; RATS; RATS, INBRED F344; SEX FACTORS; STRESS, PSYCHOLOGICAL;

EID: 79954829572     PISSN: 08891591     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbi.2011.01.014     Document Type: Article

References (53)

1. Ader R. Psychoneuroimmunology 2007, Academic Press, San Diego. fourth ed.
2. Atkins M.B., Robertson M.J., Gordon M., Lotze M.T., DeCoste M., DuBois J.S., Ritz J., Sandler A.B., Edington H.D., Garzone P.D., Mier J.W., Canning C.M., Battiato L., Tahara H., Sherman M.L. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin. Cancer Res. 1997, 3(3):409-417.
3. Bacon C.M., Petricoin E.F., Ortaldo J.R., Rees R.C., Larner A.C., Johnston J.A., O'Shea J.J. Interleukin 12 induces tyrosine phosphorylation and activation of STAT4 in human lymphocytes. Proc. Natl. Acad. Sci. USA 1995, 92(16):7307-7311.
4. Barker L.A., Dazin P.F., Levine J.D., Green P.G. Sympathoadrenal-dependent sexually dimorphic effect of nonhabituating stress on in vivo neutrophil recruitment in the rat. Br. J. Pharmacol. 2005, 145(7):872-879.
5. Barlozzari T., Leonhardt J., Wiltrout R.H., Herberman R.B., Reynolds C.W. Direct evidence for the role of LGL in the inhibition of experimental tumor metastases. J. Immunol. 1985, 134(4):2783-2789.
6. Bartal I., Melamed R., Greenfeld K., Atzil S., Glasner A., Domankevich V., Naor R., Beilin B., Yardeni I.Z., Ben-Eliyahu S. Immune perturbations in patients along the perioperative period: alterations in cell surface markers and leukocyte subtypes before and after surgery. Brain Behav. Immun. 2010, 24(3):376-386.
7. Ben-Eliyahu S. The promotion of tumor metastasis by surgery and stress: immunological basis and implications for psychoneuroimmunology. Brain Behav. Immun. 2003, 17(Suppl. 1):S27-S36.
8. Ben-Eliyahu S., Page G.G. In vivo assessment of natural killer activity in rats. Prog. Neuroendocrineimmunol. 1992, 5:199-214.
9. Ben-Eliyahu S., Page G.G., Shakhar G., Taylor A.N. Increased susceptibility to metastasis during pro-oestrus/oestrus in rats: possible role of oestradiol and natural killer cells. Br. J. Cancer 1996, 74(12):1900-1907.
10. Ben-Eliyahu S., Page G.G., Yirmiya R., Taylor A.N. Acute alcohol intoxication suppresses natural killer cell activity and promotes tumor metastasis. Nat. Med. 1996, 2(4):457-460.
11. Ben-Eliyahu, S., Rosenne, E., Sorski, L., Levi, B., 2010. Second thoughts on the role of glucocorticoids in the in vivo suppression of NK activity following stress. In: Lecture Presentation in the 17th Annual Meeting of the PsychoNeuroImmunology Research Society, Trinity College Dublin, Ireland.
12. Ben-Eliyahu S., Shakhar G., Shakhar K., Melamed R. Timing within the oestrous cycle modulates adrenergic suppression of NK activity and resistance to metastasis: possible clinical implications. Br. J. Cancer 2000, 83(12):1747-1754.
13. Bouman A., Heineman M.J., Faas M.M. Sex hormones and the immune response in humans. Hum. Reprod. Update 2005, 11(4):411-423.
14. Cohen L., de Moor C., Devine D., Baum A., Amato R.J. Endocrine levels at the start of treatment are associated with subsequent psychological adjustment in cancer patients with metastatic disease. Psychosom. Med. 2001, 63(6):951-958.
15. 2+ and tyrosine signaling pathways in human neutrophils. J. Immunol. 1998, 161(7):3737-3745.
16. Colombo M.P., Trinchieri G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 2002, 13(2):155-168.
17. Cui J., Shin T., Kawano T., Sato H., Kondo E., Toura I., Kaneko Y., Koseki H., Kanno M., Taniguchi M. Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors. Science 1997, 278(5343):1623-1626.
18. Da Silva J.A. Sex hormones, glucocorticoids and autoimmunity: facts and hypotheses. Ann. Rheum. Dis. 1995, 54(1):6-16.
19. Dengler H.G., Hengstmann J.H. Metabolism and pharmacokinetics of orciprenaline in various animal species and man. Arch. Int. Pharmacodyn. Ther. 1976, 223(1):71-87.
20. Desai B.B., Quinn P.M., Wolitzky A.G., Mongini P.K., Chizzonite R., Gately M.K. IL-12 receptor. II. Distribution and regulation of receptor expression. J. Immunol. 1992, 148(10):3125-3132.
21. Elenkov I.J., Chrousos G.P., Wilder R.L. Neuroendocrine regulation of IL-12 and TNF-alpha/IL-10 balance. Clinical implications. Ann. NY Acad. Sci. 2000, 917:94-105.
22. Elenkov I.J., Webster E.L., Torpy D.J., Chrousos G.P. Stress, corticotropin-releasing hormone, glucocorticoids, and the immune/inflammatory response: acute and chronic effects. Ann. NY Acad. Sci. 1999, 876:1-11. (discussion 11-13).
23. Fidler I.J. The organ microenvironment and cancer metastasis. Differentiation 2002, 70(9-10):498-505.
24. Ghanta V.K., Hiramoto R.N., Solvason H.B., Spector N.H. Neural and environmental influences on neoplasia and conditioning of NK activity. J. Immunol. 1985, 135(Suppl. 2):S848-S852.
25. Goldfarb Y., Benish M., Rosenne E., Melamed R., Levi B., Glasner A., Ben-Eliyahu S. CpG-C oligodeoxynucleotides limit the deleterious effects of beta-adrenoceptor stimulation on NK cytotoxicity and metastatic dissemination. J. Immunother. 2009, 32(3):280-291.
26. Grohmann U., Belladonna M.L., Bianchi R., Orabona C., Ayroldi E., Fioretti M.C., Puccetti P. IL-12 acts directly on DC to promote nuclear localization of NF-kappaB and primes DC for IL-12 production. Immunity 1998, 9(3):315-323.
27. Hurteau J.A., Blessing J.A., DeCesare S.L., Creasman W.T. Evaluation of recombinant human interleukin-12 in patients with recurrent or refractory ovarian cancer: a gynecologic oncology group study. Gynecol. Oncol. 2001, 82(1):7-10.
28. Kant G.J., Lenox R.H., Bunnell B.N., Mougey E.H., Pennington L.L., Meyerhoff J.L. Comparison of stress response in male and female rats: pituitary cyclic AMP and plasma prolactin, growth hormone and corticosterone. Psychoneuroendocrinology 1983, 8(4):421-428.
29. Kelley K.W., Bluthe R.M., Dantzer R., Zhou J.H., Shen W.H., Johnson R.W., Broussard S.R. Cytokine-induced sickness behavior. Brain Behav. Immun. 2003, 17(Suppl. 1):S112-S118.
30. Le Mevel J.C., Abitbol S., Beraud G., Maniey J. Dynamic changes in plasma adrenocorticotrophin after neurotropic stress in male and female rats. J. Endocrinol. 1978, 76(2):359-360.
31. 4+ T cells. Anticancer Res. 1997, 17(6D):4259-4268.
32. Mataradze G.D., Kurabekova R.M., Rozen V.B. The role of sex steroids in the formation of sex-differentiated concentrations of corticosteroid-binding globulin in rats. J. Endocrinol. 1992, 132(2):235-240.
33. Mehrotra P.T., Wu D., Crim J.A., Mostowski H.S., Siegel J.P. Effects of IL-12 on the generation of cytotoxic activity in human CD8+ T lymphocytes. J. Immunol. 1993, 151(5):2444-2452.
34. Melamed R., Rosenne E., Benish M., Goldfarb Y., Levi B., Ben-Eliyahu S. The marginating-pulmonary immune compartment in rats: characteristics of continuous inflammation and activated NK cells. J. Immunother. 2010, 33(1):16-29.
35. Melamed R., Rosenne E., Shakhar K., Schwartz Y., Abudarham N., Ben-Eliyahu S. Marginating pulmonary-NK activity and resistance to experimental tumor metastasis: suppression by surgery and the prophylactic use of a beta-adrenergic antagonist and a prostaglandin synthesis inhibitor. Brain Behav. Immun. 2005, 19(2):114-126.
36. Naor R., Domankevich V., Shemer S., Sominsky L., Rosenne E., Levi B., Ben-Eliyahu S. Metastatic-promoting effects of LPS: sexual dimorphism and mediation by catecholamines and prostaglandins. Brain Behav. Immun. 2009, 23(5):611-621.
37. Nishimura T., Nakui M., Sato M., Iwakabe K., Kitamura H., Sekimoto M., Ohta A., Koda T., Nishimura S. The critical role of Th1-dominant immunity in tumor immunology. Cancer Chemother. Pharmacol. 2000, 46(Suppl.):S52-S61.
38. Ottenhof P.C., Morales A., Baines M.G. Quantitation of a whole blood assay for human natural killer cell activity. J. Immunol. Methods 1981, 42(3):305-318.
39. Page G.G., Ben-Eliyahu S. Increased surgery-induced metastasis and suppressed natural killer cell activity during proestrus/estrus in rats. Breast Cancer Res. Treat. 1997, 45(2):159-167.
40. Page G.G., Fennelly A.M., Littleton-Kearney M.T., Ben-Eliyahu S. Male-female differences in the impact of beta-adrenoceptor stimulation on resistance to experimental metastasis: exploring the effects of age and gonadal hormone involvement. J. Neuroimmunol. 2008, 193(1-2):113-119.
41. Portielje J.E., Kruit W.H., Schuler M., Beck J., Lamers C.H., Stoter G., Huber C., de Boer-Dennert M., Rakhit A., Bolhuis R.L., Aulitzky W.E. Phase I study of subcutaneously administered recombinant human interleukin 12 in patients with advanced renal cell cancer. Clin. Cancer Res. 1999, 5(12):3983-3989.
42. Robertson M.J., Soiffer R.J., Wolf S.F., Manley T.J., Donahue C., Young D., Herrmann S.H., Ritz J. Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF. J. Exp. Med. 1992, 175(3):779-788.
43. Rosenberg S.A., Yang J.C., Schwartzentruber D.J., Hwu P., Marincola F.M., Topalian S.L., Restifo N.P., Dudley M.E., Schwarz S.L., Spiess P.J., Wunderlich J.R., Parkhurst M.R., Kawakami Y., Seipp C.A., Einhorn J.H., White D.E. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 1998, 4(3):321-327.
44. Rosenne E., Shakhar G., Melamed R., Schwartz Y., Erdreich-Epstein A., Ben-Eliyahu S. Inducing a mode of NK-resistance to suppression by stress and surgery: a potential approach based on low dose of poly I-C to reduce postoperative cancer metastasis. Brain Behav. Immun. 2007, 21(4):395-408.
45. Schwartz Y., Avraham R., Benish M., Rosenne E., Ben-Eliyahu S. Prophylactic IL-12 treatment reduces postoperative metastasis: mediation by increased numbers but not cytotoxicity of NK cells. Breast Cancer Res. Treat. 2008, 107(2):211-223.
46. Shakhar G., Ben-Eliyahu S. In vivo beta-adrenergic stimulation suppresses natural killer activity and compromises resistance to tumor metastasis in rats. J. Immunol. 1998, 160(7):3251-3258.
47. Smyth M.J., Cretney E., Kershaw M.H., Hayakawa Y. Cytokines in cancer immunity and immunotherapy. Immunol. Rev. 2004, 202:275-293.
48. Stanton A.L., Snider P.R. Coping with a breast cancer diagnosis: a prospective study. Health Psychol. 1993, 12(1):16-23.
49. Tan K.S., McFarlane L.C., Lipworth B.J. Loss of normal cyclical beta 2 adrenoceptor regulation and increased premenstrual responsiveness to adenosine monophosphate in stable female asthmatic patients. Thorax 1997, 52(7):608-611.
50. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 2003, 3(2):133-146.
51. Trinchieri G., Scott P. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions. Res. Immunol. 1995, 146(7-8):423-431.
52. Uji M., Yoshida K., Shintani-Ishida K., Morimoto K. Sex difference in norepinephrine surge in response to psychological stress through nitric oxide in rats. Life Sci. 2007, 80(9):860-866.
53. Wu C.Y., Wang K., McDyer J.F., Seder R.A. Prostaglandin E2 and dexamethasone inhibit IL-12 receptor expression and IL-12 responsiveness. J. Immunol. 1998, 161(6):2723-2730.